SugarLo Company

SugarLo Bio is a biotechnology company pioneering the field of glycobiology to develop a new class of medicines. The company focuses on the "glyco-code," the complex patterns of sugars on the surface of cells that regulate immune responses and disease progression. By leveraging its proprietary platform to identify and modulate sugar-binding proteins (lectins), SugarLo Bio aims to create targeted therapies for oncology, immunology, and inflammatory diseases. The company is currently in the pre-clinical stage, advancing a pipeline of candidates that target glycan-protein interactions to restore immune balance and treat chronic conditions.